Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 + oxaliplatin + irinotecan vs S-1 + cisplatin in metastatic or relapsed gastric cancer (phase III)
KCT0003166Phase 3Recruiting
- Sponsor
- Hallym University Medical Center
- Start
- Sep 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tegafur, oxaliplatin, irinotecan, cisplatin in gastric cancer (GC), sponsored by Hallym University Medical Center. Started Sep 2019; status: recruiting.
02
Drugs
tegafuroxaliplatinirinotecancisplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0003166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003166.